<DOC>
	<DOCNO>NCT03041688</DOCNO>
	<brief_summary>This phase Ib trial study side effect best dose murine double minute chromosome 2 ( MDM2 ) inhibitor AMG-232 give together decitabine treat patient acute myeloid leukemia come back , respond treatment , newly diagnose . MDM2 inhibitor AMG-232 may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , decitabine , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving MDM2 inhibitor AMG-232 together decitabine together may work well treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>MDM2 Inhibitor AMG-232 Decitabine Treating Patients With Relapsed , Refractory , Newly-Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate toxicity MDM2 inhibitor AMG-232 ( AMG-232 ) combination decitabine ( 20 mg/m^2 10 day ) , determine maximum tolerate dose ( MTD ) /recommended phase 2 dose ( RP2D ) AMG-232 combination standard dose decitabine . SECONDARY OBJECTIVES : I . To evaluate pharmacokinetic ( PK ) profile AMG-232 decitabine use combination . II . To evaluate tumor suppressor protein 53 ( p53 ) signal induce AMG-232 decitabine measure macrophage inhibitory cytokine-1 ( MIC-1 ) induction . III . To correlate AMG-232 decitabine exposure pharmacodynamics endpoint ( efficacy , toxicity , change p53 signal ) . TERTIARY OBJECTIVES : I . To evaluate response rate ( RR ) progression free survival ( PFS ) AMG-232 decitabine acute myeloid leukemia ( AML ) . II . To evaluate potential predictive biomarkers response AMG-232 decitabine AML . III . To evaluate pharmacodynamic ( PD ) effect AMG-232 decitabine AML blast . IV . To determine variability decitabine incorporation genomic deoxyribonucleic acid ( DNA ) correlate systemic pharmacokinetics exposure-response relationship . OUTLINE : This dose-escalation study MDM2 inhibitor AMG-232 . Patients receive decitabine intravenously ( IV ) 1 hour day 1-10 MDM2 inhibitor AMG-232 orally ( PO ) daily ( QD ) day 4-10 18-24 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Relapsed/refractory AML ( &gt; = 5 % blast bone marrow extramedullary leukemia ) newly diagnose AML patient candidate ( age &gt; = 70 year ; adverse cytogenetics , e.g. , define Medical Research Council [ MRC ] Prognostic Groupings ; secondary AML ; organ dysfunction arise significant comorbidities directly link leukemia ; Eastern Cooperative Oncology Group [ ECOG ] = 2 ) willing undergo intensive chemotherapy Patients must measureable disease define presence &gt; = 5 % blast bone marrow extramedullary leukemia Eligible patient must show evidence wildtype ( WT ) p53 assessed central DNA sequencing conduct Dr. Jeffrey Sklar 's laboratory Yale University Cancer Center ; note , since patient AML rapidly proliferate disease , patient enrol begin treatment prior obtain result test ; patient find TP53 mutate remove study continue single agent decitabine ; however patient continue follow toxicity ECOG performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) Total bilirubin &lt; 1.5 x institutional upper limit normal ( ULN ) ( &lt; 2.0 x ULN subject document Gilbert 's syndrome &lt; 3.0 x ULN subject indirect bilirubin level suggest extrahepatic source elevation ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) alanine aminotransferase ( ALT ) ( serum glutamic pyruvic transaminase [ SGPT ] ) = &lt; 2.5 x ULN Alkaline phosphatase &lt; 2.0 x ULN ( liver bone metastasis present , &lt; 3.0 x ULN ) Body surface area ( BSA ) normalize creatinine clearance &gt; = 60 mL/min/1.73 m^2 ( use CockcroftGault creatinine clearance [ CrCl ] ) Prothrombin time ( PT ) partial thromboplastin time ( PTT ) &lt; 1.5 x upper limit normal ( ULN ) , OR international normalize ratio ( INR ) &lt; 1.5 Corrected QT interval ( QTc ) = &lt; 470 msec ( base average screen triplicate ) Patient must willing submit blood sample bone marrow sample PK PD analyse exploratory biomarkers Women childbearing potential must agree use adequate contraception prior study entry duration study participation 5 week ( woman ) receive last dose AMG 232 ; woman become pregnant suspect pregnant partner participate study , inform treat physician immediately ; men treat enrolled protocol must also agree use adequate contraception prior study , duration study participation , 3 month completion AMG 232 administration Adequate method effective birth control include sexual abstinence ( men , woman ) ; vasectomy ; condom spermicide ( men ) combination barrier method , hormonal birth control intrauterine device ( IUD ) ( woman ) Ability understand willingness sign write informed consent document Acute promyelocytic leukemia ( 15 ; 17 ) ( q22 ; q12 ) and/or PMLRARA molecular rearrangement Core binding factor ( CBF ) AML ( inv [ 16 ] /t [ 16 ; 16 ] [ 8 ; 21 ] ) previously untreated patient Unresolved toxicity prior antitumor therapy , define resolved Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 grade 0 1 , level dictate eligibility criterion exception alopecia ( grade 2 3 toxicity prior antitumor therapy consider irreversible [ define present stable &gt; 6 month ] , ifosfamiderelated proteinuria , may allow otherwise describe exclusion criterion AND agreement allow investigator sponsor ) Patients receive investigational agent Major surgery within 28 day study day 1 Patients known central nervous system involvement time study entry exclude clinical trial History allergic reaction attribute compound similar chemical biologic composition AMG 232 decitabine All herbal medicine ( e.g. , St. John 's wort ) , vitamin , supplement consume subject within 30 day prior receive first dose AMG 232 , continue use , applicable , review principal investigator Use know CYP3A4 substrates narrow therapeutic window ( alfentanil , astemizole , cisapride , dihydroergotamine , pimozide , quinidine , sirolimus , terfanide ) within 14 day prior receive first dose AMG 232 permit ; medication ( fentanyl oxycodone ) may allow per investigator 's assessment/evaluation Treatment medication know cause QTc interval prolongation within 7 day study day 1 permit unless approve sponsor ; use ondansetron permit treatment nausea vomit Current use warfarin , factor Xa inhibitor direct thrombin inhibitor Note : Low molecular weight heparin prophylactic low dose warfarin permit ; PT/PTT must meet inclusion criterion ; subject take warfarin must INR follow closely Uncontrolled intercurrent illness include , limited , active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; patient receive antimicrobial agent may eligible patient remain afebrile hemodynamically stable 72 hour ; patient myocardial infarction within 6 month study day 1 , symptomatic congestive heart failure ( New York Heart Association ( NYHA ) class III high ) , unstable angina , cardiac arrhythmia require medication exclude Patients gastrointestinal ( GI ) tract disease cause inability take oral medication , malabsorption syndrome , requirement intravenous alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease , ulcerative colitis ) Patients history bleed diathesis Positive hepatitis B surface antigen ( HepBsAg ) ( indicative chronic hepatitis B ) , positive hepatitis total core antibody negative HBsAG ( suggestive occult hepatitis B ) , detectable Hepatitis C virus ribonucleic acid RNA polymerasechain reaction ( PCR ) assay ( indicative active hepatitis C screen generally do hepatitis C antibody ( HepCAb ) , follow hepatitis C virus RNA PCR HepCAb positive ) . Human immunodeficiency virus ( HIV ) patient positive human immunodeficiency virus ( HIV ) NOT exclude study , HIVpositive patient must : A stable regimen highly active antiretroviral therapy ( HAART ) No requirement concurrent antibiotic antifungal agent prevention opportunistic infection A CD4 count 250 cells/mcL undetectable HIV viral load standard PCRbased test Men woman reproductive potential unwilling practice acceptable method effective birth control study 5 week ( woman ) 3 month ( men ) receive last dose AMG 232 ; acceptable method effective birth control include sexual abstinence ( men , woman ) ; vasectomy ; condom spermicide ( men ) combination barrier method , hormonal birth control IUD ( woman ) Pregnant woman exclude study ; breastfeed discontinue mother treated AMG 232 Women lactating/breast feeding plan breastfeed study 1 week receive last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>